Neogen/$NEOG
1D1W1MYTD1Y5YMAX
Capital at risk
About Neogen
Neogen Corp is develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Its Food Safety segment consists mainly of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. It also have products to determine food quality and nutritional components. Its segments are Food, Animal safety. Majority of revenue comes from Food Safety. It has presence in United states, and International market.
- Ticker
- $NEOG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,636
- Headquarters
- Lansing, United States
- Website
- www.neogen.com
Neogen Metrics
BasicAdvanced
$2.7B
-
-$0.04
1.77
-
Price and volume
Market cap
$2.7B
Beta
1.77
52-week high
$12.91
52-week low
$5.10
Average daily volume
2M
Financial strength
Current ratio
3.822
Quick ratio
2.101
Long term debt to equity
0.379
Total debt to equity
0.388
Interest coverage (TTM)
-0.31%
Profitability
EBITDA (TTM)
94.7
Gross margin (TTM)
47.37%
Net profit margin (TTM)
-0.91%
Operating margin (TTM)
-2.48%
Effective tax rate (TTM)
12.22%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-0.33%
Return on equity (TTM)
-0.38%
Valuation
Price to revenue (TTM)
3.136
Price to book
1.31
Price to tangible book (TTM)
-10.03
Price to free cash flow (TTM)
85.569
Free cash flow yield (TTM)
1.17%
Free cash flow per share (TTM)
0.147
Growth
Revenue change (TTM)
-2.72%
Earnings per share change (TTM)
-99.21%
3-year revenue growth (CAGR)
1.91%
10-year revenue growth (CAGR)
10.48%
3-year earnings per share growth (CAGR)
-30.87%
10-year earnings per share growth (CAGR)
-19.73%
What the Analysts think about Neogen
Analyst ratings (Buy, Hold, Sell) for Neogen stock.
Analyst projections of the future price of Neogen stock.
Bulls say / Bears say
Neogen’s second-quarter fiscal 2026 revenue of $224.7 million exceeded analyst consensus of $207.3 million, delivering 2.9% core growth and prompting management to raise full-year fiscal 2026 revenue guidance to $845–$855 million. (Reuters)
Neogen announced the sale of its Genomics business to Zoetis for $160 million, expected to close by the first half of fiscal 2027, accelerating debt reduction and targeting net debt/adjusted EBITDA below three times by year-end 2026. (Reuters)
In the fourth quarter of fiscal 2026, Food Safety core revenue grew 5.8%, the highest quarterly rate since FY 2023, signaling strong momentum in Neogen’s core business. (Nasdaq)
Total revenue declined to $870.4 million in fiscal year 2026, down 2.7% from $894.7 million a year earlier, reflecting ongoing headwinds. (SEC)
Animal Safety segment revenue fell 10.7% year-over-year to $229.3 million, as third-party supplier quality issues weighed on segment performance. (SEC)
Gross margin contracted to 46.9% in fiscal 2026 from 47.1% in fiscal 2025, pressured by volume decreases and duplicative costs from the Petrifilm manufacturing transition. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Neogen Financial Performance
Revenues and expenses
Neogen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neogen News
AllArticlesVideos
Funds containing Neogen
AllUSDEURGBP
Fund name | Fund size | $NEOG weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.28% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.28% |
iShares Healthcare Innovation£DRDR | £1B | 0.28% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.15% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.